FY2026 Earnings Forecast for RNA Issued By HC Wainwright

Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) – Investment analysts at HC Wainwright lifted their FY2026 earnings per share estimates for Avidity Biosciences in a research note issued on Friday, November 13th. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will earn ($3.51) per share for the year, up from their prior estimate of ($5.61). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Avidity Biosciences’ current full-year earnings is ($4.45) per share. HC Wainwright also issued estimates for Avidity Biosciences’ Q4 2026 earnings at ($1.05) EPS, Q1 2027 earnings at ($1.12) EPS, Q2 2027 earnings at ($1.21) EPS, Q3 2027 earnings at ($1.30) EPS, Q4 2027 earnings at ($1.44) EPS and FY2027 earnings at ($5.07) EPS.

Avidity Biosciences (NASDAQ:RNA – Get Free Report) last announced its earnings results on Thursday, November 12th. The biotechnology company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.56. The business had revenue of $15.32 million for the quarter, compared to the consensus estimate of $15.00 million.

Other research analysts have also recently issued reports about the stock. Weiss Ratings raised shares of Avidity Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday. Roth Capital started coverage on shares of Avidity Biosciences in a report on Thursday, October 22nd. They issued a “buy” rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $33.00.

Get Our Latest Analysis on Avidity Biosciences

Avidity Biosciences Price Performance

Shares of Avidity Biosciences stock opened at $6.43 on Tuesday. The company has a 50-day moving average of $8.49 and a 200 day moving average of $17.92. The firm has a market cap of $110.02 million and a price-to-earnings ratio of -2.99. Avidity Biosciences has a 1 year low of $6.36 and a 1 year high of $16.77.

About Avidity Biosciences

(Get Free Report)

Avidity Biosciences is a biotechnology company focused on developing RNA-based medicines for diseases that affect muscle. Its Antibody Oligonucleotide Conjugate (AOC) platform combines antibodies with oligonucleotides to help deliver RNA-targeting treatments into muscle cells. The company’s research and clinical pipeline has included programs for neuromuscular disorders such as myotonic dystrophy type 1 and Duchenne muscular dystrophy. Avidity was founded in 2012 and is based in San Diego, California.

Read More

Earnings History and Estimates for Avidity Biosciences (NASDAQ:RNA)

Receive News & Ratings for Avidity Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avidity Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.